Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 29;28(9):1872–1882. doi: 10.1038/s41591-022-01916-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 9 — Gene expression was measured with PanCancer Immune Profiling panel in Zuma 1 (a,b) tumour biopsies from subsets 1, 2, and 3, and (c,d) in pretreatment tumour biopsies from patients with CR (n=22 total [20 CR, 2 PR]) vs. nonCR (n=7 total [4 SD, 3 PD]) a, Volcano plots of B-cell lineage (top panel) and CTA (bottom panel) gene expression from subset 2 (n = 12) and subset 3 (n = 3). The plot was constructed using log2(fold change) and –log10(P value) for all genes analysed by PanCancer Immune Profiling panel. Red dots represent the top differentially expressed genes with P<0.01 (two-sided t.test without adjustment). b, Evolution of B-cell and CTA gene expression across FFPE biopsies from subsets 1 (n=19), 2 (n=14), and 3 (n=2). c, Volcano plots of B-cell lineage (left) and CTA-related (right) gene expression in pretreatment tumour biopsies of patients with CR vs. nonCR outcomes. P values were derived with a Kruskal-Wallis test. d, Gene expression of CTA-related genes (MAGE-B2 and PRAME) in pretreatment tumour biopsies of patients with CR/PR vs. SD/PD outcomes. P values were derived with two-sided Wilcoxon test.AICDA, activation-induced cytidine deaminase; axi-cel, axicabtagene ciloleucel; BTK, Bruton tyrosine kinase; CR, complete response; CTA, cancer testis antigen; FFPE, formalin-fixed paraffin-embedded; IKBKB, inhibitor of nuclear factor kappa B kinase subunit B; ; IS21, Immunosign21; MAGE, melanoma-associated antigen; PAX5, paired box protein 5; PD, progressive disease; POU2AF1, POU domain class 2-associating factor 1; PR, partial response; PRAME, preferentially expressed antigen in melanoma; SAA1, serum amyloid A1; SD, stable disease; TME, tumour microenvironment.